Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...

Bridgewater Associates made a fresh bet on EV maker Tesla Inc. late last year, as it exited memory chip maker Micron ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen Richter ...

These three premier ASX healthcare stocks just reported half-yearly earnings – and each saw its share price dip…So, is now the time to buy?

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

S&P 500 futures ticked up marginally early Friday after President Donald Trump held off on imposing new reciprocal tariffs.

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...

Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.